x min read

BPS initiates coverage on Ibio Inc (NYSEMKT:IBIO)

BPS initiates coverage on Ibio Inc (NYSEMKT:IBIO)
Written by
Aaron Smith
Published on
October 27, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook

On 9th October’14, BrilliantPennyStocks.com initiated coverage on IBIO. The stock moved up by 105.48% since the coverage was initiated.

Biotech firm Ibio Inc (NYSEMKT:IBIO) share price tanked by nearly 8 percent during trading on 24th October. The downward spiral in the stock’s prospects started early last week when drug makers Icon Genetics AG and A&M Lab released press statements, which contradicted IbioInc claims. This sent the stock nose diving during trading last week, leading to a 53% dip in valuation for the week.

More Trouble Brewing – Law Firms Get Into The Act

On the back of huge losses suffered by the investor community due to the sudden dip in valuation of Ibio Inc (NYSEMKT:IBIO) a host of law firms have served notice on the management of the cornered drug maker. They plan to investigate if key officials of the drug maker were involved in “potential securities fraud” by releasing misleading claims to the media.

Reasons For The Sudden Dip In Investor Confidence

Ibio Inc (NYSEMKT:IBIO) got severely impacted after online reports emerged early last week that the drug maker commercial relationship with rival drug maker Caliber Biotherapeutics excludes any potential joint development of Ebola treating drug.

Another damaging statement emerged from drug maker A&M Lab. A&M Lab clarified that any new “plant-based ZMapp manufacturing” of experimental drug to treat Ebola hast to conform to methods which are “identical to what the maker of the drug had already vetted in animals.” This meant that Ibio Inc (NYSEMKT:IBIO) patented method to produce the experimental drug cannot not be used at this stage to manufacture the much in demand Ebola drugs.

Ibio Inc Claims

Over the past three weeks, the management team at Ibio Inc (NYSEMKT:IBIO) had authorized a series of updates, which were contrary to the above assertions by A&M Labs and Caliber Bio. On 16th October, Ibio had issued a press release indicating that its patented platform is applicable to produce Ebola virus. It had also claimed that it is closely working with Caliber Bio to further augment its Ebola offering.

About BrilliantPennyStocks

BSP provides sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. BPS provides alerts to investors and traders on stocks that could potentially breakout. To obtain text message stock alerts service, text the word Avauncer to 95577 from your cell phone. Additionally, BPS provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.

Disclosure: BrilliantPennyStocks is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://brilliantpennystocks.com/disclaimer/ for complete risks and disclosures.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.